Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc. (FHTX): 3 pipeline candidates · ~14 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
14.3 months
D/E -3.91 · 18% dilution
Lead: Phase 1
3 candidates
N/A
N/A
A transparent, data-derived signal for Foghorn Therapeutics Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$232.8M
Cash
$90.9M
Quarterly Burn
$25.3M
Runway
14.3 mo
Revenue
$3.3M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| fhd-286 | Phase 1 |
| fhd-909 | Phase 1 |
| low dose cytarabine | Phase 1 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
104
Total value held
$216.8M
| Holder | Shares | Value |
|---|---|---|
| flagship pioneering, llc | 12,674,120 | $60.6M |
| fmr llc | 6,047,198 | $28.9M |
| bvf inc/il | 5,842,000 | $27.9M |
| deerfield management company, l.p. | 4,394,367 | $21.0M |
| vanguard capital management llc | 2,990,178 | $14.3M |
| raymond james financial inc | 2,602,382 | $12.4M |
| blackrock, inc. | 2,364,866 | $11.3M |
| euclidean capital llc | 1,573,761 | $7.5M |
| geode capital management, llc | 848,172 | $4.1M |
| state street corp | 679,787 | $3.2M |
Showing top 10 of 104 institutional holders of Foghorn Therapeutics Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Foghorn Therapeutics Inc.'s pipeline?
Foghorn Therapeutics Inc. (FHTX) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Foghorn Therapeutics Inc.'s lead drug candidate?
Foghorn Therapeutics Inc.'s most advanced tracked candidate is fhd-286 (Phase 1) for Advanced Hematologic Malignancy.
What is Foghorn Therapeutics Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Foghorn Therapeutics Inc. has approximately 14.3 months of cash runway.
What is Foghorn Therapeutics Inc.'s market capitalization?
Foghorn Therapeutics Inc.'s market capitalization is approximately $232.8M.
Who is the CEO of Foghorn Therapeutics Inc.?
Mr. Adrian H. B. Gottschalk is the chief executive officer of Foghorn Therapeutics Inc. (FHTX).
Get the full picture on Foghorn Therapeutics Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.